Actively Recruiting
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
Led by Richard Fatica · Updated on 2026-03-06
20
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
Sponsors
R
Richard Fatica
Lead Sponsor
S
Santa Barbara Nutrients
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.
CONDITIONS
Official Title
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult (18 years or older)
- Diagnosis of ADPKD by a physician
- Estimated glomerular filtration rate (eGFR) 6 30 mL/min/1.73 m2 at screening using CKD-EPI equation
- Controlled blood pressure (entry reading <140/90) including use of blood pressure medications
- Body mass index (BMI) 6 25 (accounting for muscle mass)
- Own an at-home blood pressure monitor
- Able to complete study activities such as attending online classes, completing questionnaires, and using medical devices properly
You will not qualify if you...
- Allergy or intolerance to ingredients in the provided medical food
- Severe or rare health conditions that pose safety risks, including history of hyperkalemia, heart failure, liver cirrhosis, chronic kidney disease stage 4 or greater, HIV infection, chronic drug or alcohol abuse, chronic malabsorption syndrome, malignancy (except non-melanoma skin cancer), autoimmune disease
- Pregnant, planning to be pregnant, or nursing during the study
- Chronic recurrent urinary tract infections (3 or more per year)
- Diagnosis of aneurysm
- Indigestion due to low stomach acid (hypochlorhydria)
- Any condition deemed unsuitable for study participation by the enrolling physician
- Current use of KetoCitra or similar medical food
- Use of urine alkalizing agents such as sodium bicarbonate or potassium citrate, citrate treatments, immunosuppressive treatments, Tolvaptan, potassium-sparing diuretics, somatostatin analogs, aluminum-containing supplements or medications, or SGLT2 inhibitors
- Participation in another therapeutic intervention trial
- Following a highly specialized or extreme diet incompatible with the study program
- Food sensitivities or allergies incompatible with the study diet
- Already following a ketogenic diet or related fasting regimen
- Current or past disordered eating or feeding behaviors
- History of gastric bypass surgery
- Active diagnosis of ulcerative colitis, irritable bowel syndrome, Crohn's disease, or gallbladder disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
Research Team
C
Chloe Booth
CONTACT
R
Richard Fatica, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here